Status:

ACTIVE_NOT_RECRUITING

An Observational Cohort Study to Obese Patients With Weight Cycling

Lead Sponsor:

Peking Union Medical College Hospital

Conditions:

Weight Cycling

Obesity

Eligibility:

All Genders

18-50 years

Brief Summary

Medical nutritional weight loss was effective in reducing body weight and waist circumference and improving a range of cardiovascular disease risk factors in obese patients, with an average effective ...

Eligibility Criteria

Inclusion

  • Normal weight (18.5 ≤ BMI \< 24 kg/m2) or obese (28 ≤ BMI \< 35 kg/m2);
  • Aged 18 to 50 years old;
  • Han nationality;
  • Able to follow the weight-loss prescription;
  • Able to sign consent independently;
  • Definition of Weight cycling: Loss weight more than once in the past 3 years, and weight regain exceeds 5% or more of the baseline weight of losing weight.

Exclusion

  • Bodyweight has changed more than ±10% in the past year;
  • Taking drugs known to affect body weight (orlistat, GLP-1 receptor agonists, etc.);
  • Taking drugs known to affect glucolipid metabolism (such as sulfonylureas, biguanides, acarbose, or insulin) have been taken in the past 6 months or at present; Lipid-lowering drugs such as statins, bate, niacin, and ezetimibe; Diuretics, β -blockers and other antihypertensive drugs; Glucocorticoid, thyroid hormone, etc.);
  • Women who are currently pregnant or nearly 3 months breastfeeding;
  • With serious eating disorders or vigorous exercise to lose weight;
  • Hard physical workers;
  • History of serious cardiovascular disease;
  • Acute, chronic, or active gastrointestinal diseases;
  • Serious systemic diseases;
  • History of serious mental disorders;
  • Cancer or active tumor;
  • Secondary obesity or drug obesity patients: including hypothalamic obesity, pituitary obesity, hypercortisolism, and hypogonadism obesity;
  • Severe liver dysfunction (ALT, AST, ALP, and TBil \> the upper limit of 2.5 times reference value);
  • Chronic kidney disease (eGFR \< 60 mL/min/1.73 m2 or eGFR \< 90 mL/min/1.73 m2 with proteinuria);
  • Those who are considered by the researcher to be poor compliance or unable to complete this research well.

Key Trial Info

Start Date :

April 8 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 20 2028

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT05311462

Start Date

April 8 2022

End Date

December 20 2028

Last Update

January 14 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100010